BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38670256)

  • 1. Recent advances in the development of DprE1 inhibitors using AI/CADD approaches.
    Chen K; Xu R; Hu X; Li D; Hou T; Kang Y
    Drug Discov Today; 2024 Jun; 29(6):103987. PubMed ID: 38670256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
    Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
    J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
    Dash S; Rathi E; Kumar A; Chawla K; Kini SG
    Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic molecules as DprE1 inhibitors: A patent review.
    Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
    Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
    Piton J; Foo CS; Cole ST
    Drug Discov Today; 2017 Mar; 22(3):526-533. PubMed ID: 27666194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
    Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
    J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Borthwick JA; Alemparte C; Wall I; Whitehurst BC; Argyrou A; Burley G; de Dios-Anton P; Guijarro L; Monteiro MC; Ortega F; Suckling CJ; Pichel JC; Cacho M; Young RJ
    J Med Chem; 2020 Mar; 63(5):2557-2576. PubMed ID: 31922409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
    Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DprE1--from the discovery to the promising tuberculosis drug target.
    Mikusová K; Makarov V; Neres J
    Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual Screening of Small Molecular Inhibitors against DprE1.
    Zhang G; Guo S; Cui H; Qi J
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the
    Ezquerra-Aznárez JM; Degiacomi G; Gašparovič H; Stelitano G; Sammartino JC; Korduláková J; Governa P; Manetti F; Pasca MR; Chiarelli LR; Ramón-García S
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
    Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
    ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
    Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
    Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of
    Yang L; Hu X; Lu Y; Xu R; Xu Y; Ma W; Alam MS; Zhang T; Chai X; Lei Y; Ye Q; Dong X; Kang Y; Che J; Hou T; Li D
    J Med Chem; 2024 Feb; 67(3):1914-1931. PubMed ID: 38232131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
    Rogacki MK; Pitta E; Balabon O; Huss S; Lopez-Roman EM; Argyrou A; Blanco-Ruano D; Cacho M; Vande Velde CML; Augustyns K; Ballell L; Barros D; Bates RH; Cunningham F; Van der Veken P
    J Med Chem; 2018 Dec; 61(24):11221-11249. PubMed ID: 30500189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
    Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
    Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
    Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
    PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.
    Riccardi G; Pasca MR; Chiarelli LR; Manina G; Mattevi A; Binda C
    Appl Microbiol Biotechnol; 2013 Oct; 97(20):8841-8. PubMed ID: 24037308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.
    Whitehurst BC; Young RJ; Burley GA; Cacho M; Torres P; Vela-Gonzalez Del Peral L
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127192. PubMed ID: 32312582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.
    Chikhale R; Menghani S; Babu R; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
    Eur J Med Chem; 2015; 96():30-46. PubMed ID: 25874329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.